Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Aytu BioPharma Inc is a specialty pharmaceutical company commercializing novel products addressing patient needs. The company markets a portfolio of prescription products addressing large therapeutic markets. The primary care portfolio includes Natesto, the only FDA-approved nasal formulation of testosterone, ZolpiMist, the only FDA-approved oral spray prescription sleep aid, and Tuzistra XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes AcipHex Sprinkle, Cefaclor, Karbinal ER, and Poly-Vi-Flor and Tri-Vi-Flor.
Englewood, CO, 80112